拉曼显微光谱识别前列腺导管内癌:多队列验证的诊断准确性病例对照研究
研究利用拉曼显微光谱结合机器学习,在483例根治性前列腺切除标本中区分前列腺导管内癌(IDC-P)、前列腺癌(PC)和良性组织。训练队列中IDC-P与PC鉴别准确率95%±2%,独立测试队列准确率85%和91%,IDC-P与高级别前列腺上皮内瘤变鉴别准确率均>95%。
要点
- 拉曼显微光谱可高准确度区分IDC-P与PC,训练队列准确率95%±2%。
- 两独立测试队列中IDC-P鉴别准确率分别为85%和91%。
- IDC-P与HGPIN鉴别在训练和测试队列中准确率均>95%。
核心结论
- 拉曼显微光谱结合机器学习可区分IDC-P、PC与良性组织,有望辅助高危前列腺癌患者的识别。
研究设计与样本
- 诊断准确性病例对照研究,纳入3家加拿大机构1993至2013年收治的483例根治性前列腺切除标本。
- 标本为福尔马林固定石蜡包埋组织芯片,每例取连续切片,一张用于免疫组化HE染色定位细胞,另一张用于拉曼光谱采集。
- 每个标本平均采集7条拉曼光谱(范围4至24条,每个组织芯片芯4次采集)。
- 模型在一家机构数据上训练并交叉验证,后在另外两家独立机构数据上测试。
主要发现
- 训练队列中区分PC与良性组织的准确率、灵敏度、特异度分别为87%±5%、86%±6%、89%±8%。
- 训练队列中区分IDC-P与PC的准确率、灵敏度、特异度分别为95%±2%、96%±4%、94%±2%。
- 两个独立测试队列诊断PC的准确率分别为84%和86%,灵敏度84%和87%,特异度81%和82%。
- 两个独立测试队列识别IDC-P的准确率分别为85%和91%,灵敏度85%和88%,特异度86%和93%。
- IDC-P与HGPIN鉴别在训练和测试队列中准确率、灵敏度、特异度均>95%。
临床怎么用
- 拉曼显微光谱可作为下一代组织病理学技术,辅助确认IDC-P以识别高危前列腺癌患者。
- 该方法采用适合常规临床组织病理实验室的流程,基于石蜡包埋组织芯片采集光谱。
局限性
- 研究采用严格的IDC-P诊断标准,排除了 borderline、难以分类的病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PC) is the most frequently diagnosed cancer in North American men. Pathologists are in critical need of accurate biomarkers to characterize PC, particularly to confirm the presence of intraductal carcinoma of the prostate (IDC-P), an aggressive histopathological variant for which therapeutic options are now available. Our aim was to identify IDC-P with Raman micro-spectroscopy (RμS) and machine learning technology following a protocol suitable for routine clinical histopathology laboratories. METHODS AND FINDINGS: We used RμS to differentiate IDC-P from PC, as well as PC and IDC-P from benign tissue on formalin-fixed paraffin-embedded first-line radical prostatectomy specimens (embedded in tissue microarrays [TMAs]) from 483 patients treated in 3 Canadian institutions between 1993 and 2013. The main measures were the presence or absence of IDC-P and of PC, regardless of the clinical outcomes. The median age at radical prostatectomy was 62 years. Most of the specimens from the first cohort (Centre hospitalier de l'Université de Montréal) were of Gleason score 3 + 3 = 6 (51%) while most of the specimens from the 2 other cohorts (University Health Network and Centre hospitalier universitaire de Québec-Université Laval) were of Gleason score 3 + 4 = 7 (51% and 52%, respectively). Most of the 483 patients were pT2 stage (44%-69%), and pT3a (22%-49%) was more frequent than pT3b (9%-12%). To investigate the prostate tissue of each patient, 2 consecutive sections of each TMA block were cut. The first section was transferred onto a glass slide to perform immunohistochemistry with H&E counterstaining for cell identification. The second section was placed on an aluminum slide, dewaxed, and then used to acquire an average of 7 Raman spectra per specimen (between 4 and 24 Raman spectra, 4 acquisitions/TMA core). Raman spectra of each cell type were then analyzed to retrieve tissue-specific molecular information and to generate classification models using machine learning technology. Models were trained and cross-validated using data from 1 institution. Accuracy, sensitivity, and specificity were 87% ± 5%, 86% ± 6%, and 89% ± 8%, respectively, to differentiate PC from benign tissue, and 95% ± 2%, 96% ± 4%, and 94% ± 2%, respectively, to differentiate IDC-P from PC. The trained models were then tested on Raman spectra from 2 independent institutions, reaching accuracies, sensitivities, and specificities of 84% and 86%, 84% and 87%, and 81% and 82%, respectively, to diagnose PC, and of 85% and 91%, 85% and 88%, and 86% and 93%, respectively, for the identification of IDC-P. IDC-P could further be differentiated from high-grade prostatic intraepithelial neoplasia (HGPIN), a pre-malignant intraductal proliferation that can be mistaken as IDC-P, with accuracies, sensitivities, and specificities > 95% in both training and testing cohorts. As we used stringent criteria to diagnose IDC-P, the main limitation of our study is the exclusion of borderline, difficult-to-classify lesions from our datasets. CONCLUSIONS: In this study, we developed classification models for the analysis of RμS data to differentiate IDC-P, PC, and benign tissue, including HGPIN. RμS could be a next-generation histopathological technique used to reinforce the identification of high-risk PC patients and lead to more precise diagnosis of IDC-P.
引用
- Grosset AA, Dallaire F, Nguyen T, et al. Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. PLoS Med. 2020. PMID: 32797086. doi:10.1371/journal.pmed.1003281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。